Journal of Traditional Medical Complementary Therapies

.: REVIEW
Kurkumin ve Kurkuminoidlerin Diyabetin Komplikasyonları Üzerine Etkisi, Doz Planlaması ve Biyoyaralanımı
The Effect of Curcumin and Curcuminoids on Complications of Diabetes Dosage Planning and Bioavailable
M. Ali ÇAKIRa, Oğuzhan KESKİNa,b
aKırklareli Üniversitesi Sağlık Yüksekokulu, Beslenme ve Diyetetik Bölümü, Kırklareli, TÜRKİYE
bKırklareli Üniversitesi Sağlık Bilimleri Enstitüsü, Halk Sağlığı Yüksek Lisans Programı, Kırklareli, TÜRKİYE
J Tradit Complem Med. 2021;4(1):65-76
doi: 10.5336/jtracom.2020-74453
Article Language: TR
ÖZET
Kurkumin; kurkumin (diferuloilmetan) (%77), demetoksikurkumin (%17) ve bisdemethoksikurkumin (%3) olmak üzere Curcuma longa (zerdeçal) bitkisinin kökünden elde edilen doğal bir üründür. Diyabet, bozulmuş glukoz seviyesi ile devam eden metabolik bir hastalık olarak tanımlanmaktadır. Dünya nüfusunun artması ile Tip 2 diyabet görülme sıklığındaki artış ilişkilidir. 2040 yılında toplam dünya nüfusunun %13,5'i kadarının diyabetli olacağı tahmin edilmektedir. Diyabet ve diyabetin komplikasyonları sonucu sadece 2012 yılında 1,5 milyon insan ölmüştür. Dünya çapında büyük bir prevalansı olan diyabet ve komplikasyonları ile baş edebilmek için etkili önleme yöntemleri gereklidir. Bu yöntemlerden birsi de kurkumin takviyesi yapılmasıdır. Biyoyararlanım, besin takviyesi olarak kurkumin kullanımında ana konudur. Kurkuminin vücuttan hızlıca atılması ve gastrointestinal sistemden az miktarda absorbe edilememesi biyoyarlanımını ve farmakokinetik etkilerini sınırlamaktadır. Birçok çalışmada, kurkuminin biyoyararlanımının azlığından bahsedilmektedir ve bu yararlanma oranın artırılması için multidisipliner çalışmalara ihtiyaç olduğu belirtilmektedir. Geleneksel Çin tıbbından bu yana yapılan çalışmalarda; kurkuminin antikanser, antiinflamatuar, antioksidan gibi etkileri olan bir fitokimyasal olduğu belirtilmektedir. Kurkumin insülin direnci, hiperglisemi, hiperlipidemi ve adacık apoptozu ve nekrozu gibi diyabetin önde gelen komplikasyonlarının çoğunu olumlu şekilde etkilediği araştırmalarda gösterilmektedir. Kurkuminin klinik çalışmalarından elde edilen sonuçlarına göre diyabetik nefropati, mikroanjiyopati ve retinopatiyi tedavi etmek için etkili bir ajan olduğu gösterilmiştir. Ancak kurkumin ile ilgili yapılan çalışmaların çok azı diyabet ve komplikasyonları üzerine odaklanmıştır. Bu derlemenin amacı, kurkuminin diyabet ve komplikasyonlarını önlemek için kullanılabilirliğini incelemektir.

Anahtar Kelimeler: Kurkumin; diyabet; retinopati; nöropati; demetoksikurkumin; diyabetin komplikasyonları
ABSTRACT
Curcumin; Curcuma (turmeric) is a natural product obtained from the root of the Curcuma Longa (turmeric) plant, which is curcumin (diferuloylmethane) (77%), demetoxicurcumin (17%) and bisdemethoxycurcumin (3%). Diabetes is defined as a metabolic disease that continues with impaired glucose level. The increase in the world population is associated with an increase in the frequency of type 2 diabetes. It is estimated that 13.5% of the total world population will have diabetes in 2040. As a result of diabetes and its complications, 1.5 million people died in 2012 alone. Effective prevention methods are necessary to deal with diabetes and its complications, which is a major prevalence worldwide. One of these methods is to make curcumin supplements. Bioavailability is the main issue in the use of curcumin as a nutritional supplement. The rapid removal of curcumin from the body and its low absorption from the gastrointestinal tract limits its bioavailability and pharmacokinetic effects. In many studies, the low bioavailability of curcumin is mentioned and it is stated that multidisciplinary studies are needed to increase this utilization rate. In studies conducted since traditional Chinese medicine, curcumin is stated to be a phytochemical with effects such as anti cancer, anti-inflammatory and antioxidant. Studies show that curcumin has positive effects on many of the leading complications of diabetes, such as insulin resistance, hyperglycemia, hyperlipidemia, and islet apoptosis and necrosis. Curcumin has been shown to be an effective agent to treat diabetic nephropathy, microangiopathy and retinopathy, according to results from clinical trials. However, few studies of curcumin have focused on diabetes and its complications. The aim of this review is to examine the usability of curcumin to prevent diabetes and its complications.

Keywords: Curcumin; diabetes; retinopathy; neuropathy; demethoxycurcumin; diabetes complications
REFERENCES:
  1. Rashid K, Chowdhury S, Ghosh S, Sil PC. Curcumin attenuates oxidative stress induced NFκB mediated inflammation and endoplasmic reticulum dependent apoptosis of splenocytes in diabetes. Biochem Pharmacol. 2017;143:140-55. [Crossref]  [PubMed] 
  2. Cicero AFG, Sahebkar A, Fogacci F, Bove M, Giovannini M, Borghi C. Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial. Eur J Nutr. 2020;59(2):477-83. [Crossref]  [PubMed]  [PMC] 
  3. Su LQ, Wang YD, Chi HY. Effect of curcumin on glucose and lipid metabolism, FFAs and TNF-α in serum of type 2 diabetes mellitus rat models. Saudi J Biol Sci. 2017;24(8):1776-80. [Crossref]  [PubMed]  [PMC] 
  4. Zhang DW, Fu M, Gao SH, Liu JL. Curcumin and diabetes: a systematic review. Evid Based Complement Alternat Med. 2013;2013:636053. [Crossref]  [PubMed]  [PMC] 
  5. Ghosh S, Banerjee S, Sil PC. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update. Food Chem Toxicol. 2015;83:111-24. [Crossref]  [PubMed] 
  6. Radomska-Leśniewska DM, Osiecka-Iwan A, Hyc A, Góźdź A, Dąbrowska AM, Skopiński P. Therapeutic potential of curcumin in eye diseases. Cent Eur J Immunol. 2019;44(2):181-9. [Crossref]  [PubMed]  [PMC] 
  7. Lv J, Cao L, Zhang R, Bai F, Wei P. A curcumin derivative J147 ameliorates diabetic peripheral neuropathy in streptozotocin (STZ)-induced DPN rat models through negative regulation AMPK on TRPA1. Acta Cir Bras. 2018;33(6):533-41. [Crossref]  [PubMed] 
  8. Rivera-Mancía S, Lozada-García MC, Pedraza-Chaverri J. Experimental evidence for curcumin and its analogs for management of diabetes mellitus and its associated complications. Eur J Pharmacol. 2015 ;756:30-7. [Crossref]  [PubMed] 
  9. Jeenger MK, Shrivastava S, Yerra VG, Naidu VG, Ramakrishna S, Kumar A. Curcumin: a pleiotropic phytonutrient in diabetic complications. Nutrition. 2015;31(2):276-82. [Crossref]  [PubMed] 
  10. Roxo DF, Arcaro CA, Gutierres VO, Costa MC, Oliveira JO, Lima TFO, et al. Curcumin combined with metformin decreases glycemia and dyslipidemia, and increases paraoxonase activity in diabetic rats. Diabetol Metab Syndr. 2019;11:33. [Crossref]  [PubMed]  [PMC] 
  11. Jiang CS, Liang LF, Guo YW. Natural products possessing protein tyrosine phosphatase 1B (PTP1B) inhibitory activity found in the last decades. Acta Pharmacol Sin. 2012;33(10):1217-45. [Crossref]  [PubMed]  [PMC] 
  12. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care. 2012;35(11):2121-7. [Crossref]  [PubMed]  [PMC] 
  13. Akolade JO, Oloyede HOB, Onyenekwe PC. Encapsulation in chitosan-based polyelectrolyte complexes enhances antidiabetic activity of curcumin. J Funct Foods. 2017;35:584-94. [Crossref] 
  14. Sunagawa Y, Katanasaka Y, Hasegawa K, Morimoto T. Clinical applications of curcumin. PharmaNutrition. 2015;3(4):131-5. [Crossref] 
  15. Shehzad A, Ha T, Subhan F, Lee YS. New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur J Nutr. 2011;50(3):151-61. [Crossref]  [PubMed] 
  16. Vickers NJ. Animal communication: when i'm calling you, will you answer too? Curr Biol. 2017;27(14):R713-R715. [Crossref]  [PubMed] 
  17. Saraf-Bank S, Ahmadi A, Paknahad Z, Maracy M, Nourian M. Effects of curcumin on cardiovascular risk factors in obese and overweight adolescent girls: a randomized clinical trial. Sao Paulo Med J. 2019;137(5):414-22. [Crossref]  [PubMed] 
  18. Akbari M, Lankarani KB, Tabrizi R, Ghayour-Mobarhan M, Peymani P, Ferns G, et al. The effects of curcumin on weight loss among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2019;10:649. [Crossref]  [PubMed]  [PMC] 
  19. Baziar N, Parohan M. The effects of curcumin supplementation on body mass index, body weight, and waist circumference in patients with nonalcoholic fatty liver disease: A systematic review and dose-response meta-analysis of randomized controlled trials. Phytother Res. 2020;34(3):464-74. [Crossref]  [PubMed] 
  20. Seo KI, Choi MS, Jung UJ, Kim HJ, Yeo J, Jeon SM,et al Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res. 2008;52(9):995-1004. [Crossref]  [PubMed] 
  21. Poolsup N, Suksomboon N, Kurnianta PDM, Deawjaroen K. Effects of curcumin on glycemic control and lipid profile in prediabetes and type 2 diabetes mellitus: A systematic review and meta-analysis. PLoS One. 2019;14(4):e0215840. Retraction in: PLoS One. 2020;15(5):e0233919. [Crossref]  [PubMed]  [PMC] 
  22. Pivari F, Mingione A, Brasacchio C, Soldati L. Curcumin and type 2 diabetes mellitus: prevention and treatment. Nutrients. 2019;11(8):1837. [Crossref]  [PubMed]  [PMC] 
  23. Hodaei H, Adibian M, Nikpayam O, Hedayati M, Sohrab G. The effect of curcumin supplementation on anthropometric indices, insulin resistance and oxidative stress in patients with type 2 diabetes: a randomized, double-blind clinical trial. Diabetol Metab Syndr. 2019;11:41. [Crossref]  [PubMed]  [PMC] 
  24. Karlowicz-Bodalska K, Han S, Freier J, Smolenski M, Bodalska A. Curcuma longa as medicinal herb in the treatment of diabet-ic complications. Acta Pol Pharm. 2017;74(2):605-10. [PubMed] 
  25. Azhdari M, Karandish M, Mansoori A. Metabolic benefits of curcumin supplementation in patients with metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2019;33(5):1289-301. [Crossref]  [PubMed] 
  26. Lu X, Wu F, Jiang M, Sun X, Tian G. Curcumin ameliorates gestational diabetes in mice partly through activating AMPK. Pharm Biol. 2019;57(1):250-4. [Crossref]  [PubMed]  [PMC] 
  27. Bi X, Lim J, Henry CJ. Spices in the management of diabetes mellitus. Food Chem. 2017;217:281-93. [Crossref]  [PubMed] 
  28. Yang JW, Yeo HK, Yun JH, Lee JU. Theracurmin (Highly Bioavailable Curcumin) prevents high fat diet-induced hepatic steatosis development in mice. Toxicol Res. 2019;35(4):403-10. [Crossref]  [PubMed]  [PMC] 
  29. Ariamoghaddam AR, Ebrahimi-Hosseinzadeh B, Hatamian-Zarmi A, Sahraeian R. In vivo anti-obesity efficacy of curcumin loaded nanofibers transdermal patches in high-fat diet induced obese rats. Mater Sci Eng C Mater Biol Appl. 2018;92:161-71. Erratum in: Mater Sci Eng C Mater Biol Appl. 2020;106:110149. [Crossref]  [PubMed] 
  30. Woo HM, Kang JH, Kawada T, Yoo H, Sung MK, Yu R. Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes. Life Sci. 2007;80(10):926-31. [Crossref]  [PubMed] 
  31. Ohara K, Uchida A, Nagasaka R, Ushio H, Ohshima T. The effects of hydroxycinnamic acid derivatives on adiponectin secretion. Phytomedicine. 2009;16(2-3):130-7. [Crossref]  [PubMed] 
  32. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology. 2008;149(7):3549-58. [Crossref]  [PubMed]  [PMC] 
  33. Pérez-Torres I, Ruiz-Ramírez A, Ba-os G, El-Hafidi M. Hibiscus sabdariffa Linnaeus (Malvaceae), curcumin and resveratrol as alternative medicinal agents against metabolic syndrome. Cardiovasc Hematol Agents Med Chem. 2013;11(1):25-37. [Crossref]  [PubMed] 
  34. Wu LY, Chen CW, Chen LK, Chou HY, Chang CL, Juan CC. Curcumin attenuates adipogenesis by inducing preadipocyte apoptosis and inhibiting adipocyte differentiation. Nutrients. 2019;11(10):2307. [Crossref]  [PubMed]  [PMC] 
  35. Buonomo AR, Scotto R, Nappa S, Arcopinto M, Salzano A, Marra AM, et al. The role of curcumin in liver diseases. Arch Med Sci. 2019;15(6):1608-20. [Crossref]  [PubMed]  [PMC] 
  36. Kurt M, Atmaca A, Gürlek A. [Diabetic nephropathy]. Hacettepe Tıp Dergisi. 2004;35:12-7. [Link] 
  37. Soetikno V, Sari FR, Sukumaran V, Lakshmanan AP, Harima M, Suzuki K, et al. Curcumin decreases renal triglyceride accumulation through AMPK-SREBP signaling pathway in streptozotocin-induced type 1 diabetic rats. J Nutr Biochem. 2013;24(5):796-802. [Crossref]  [PubMed] 
  38. Wang C, He X, Huang Q, Fu X, Liu S. Physicochemical properties and application of micronized cornstarch in low fat cream. J Food Eng. 2013;116(4):881-8. [Crossref] 
  39. Sun LN, Yang ZY, Lv SS, Liu XC, Guan GJ, Liu G. Curcumin prevents diabetic nephropathy against inflammatory response via reversing caveolin-1 Tyr14 phosphorylation influenced TLR4 activation. Int Immunopharmacol. 2014;23(1):236-46. [Crossref]  [PubMed] 
  40. Platania CBM, Fidilio A, Lazzara F, Piazza C, Geraci F, Giurdanella G,et al. Retinal protection and distribution of curcumin in vitro and in vivo. Front Pharmacol. 2018;9:670. [Crossref]  [PubMed]  [PMC] 
  41. Premanand C, Rema M, Sameer MZ, Sujatha M, Balasubramanyam M. Effect of curcumin on proliferation of human retinal endothelial cells under in vitro conditions. Invest Ophthalmol Vis Sci. 2006;47(5):2179-84. [Crossref]  [PubMed] 
  42. Steigerwal R, Nebbioso M, Appendino G, Belcaro G, Ciammaichella G, Cornelli U, et al. Meriva®, a lecithinized curcumin delivery system, in diabetic microangiopathy and retinopathy. Panminerva Medica. 2012;54(1 Suppl 4):11-6. [Link] 
  43. Zheng J, Cheng J, Zheng S, Feng Q, Xiao X. Curcumin, a polyphenolic curcuminoid with its protective effects and molecular mechanisms in diabetes and diabetic cardiomyopathy. Front Pharmacol. 2018;9:472. [Crossref]  [PubMed]  [PMC] 
  44. Bulboacă AE, Porfire AS, Tefas LR, Boarescu PM, Bolboacă SD, Stănescu IC, et al. Liposomal curcumin is better than curcumin to alleviate complications in experimental diabetic mellitus. Molecules. 2019;24(5):846. [Crossref]  [PubMed]  [PMC] 
  45. Niu Y, He J, Ahmad H, Shen M, Zhao Y, Gan Z,et al. Dietary curcumin supplementation increases antioxidant capacity, upregulates nrf2 and hmox1 levels in the liver of piglet model with intrauterine growth retardation. Nutrients. 2019;11(12):2978. [Crossref]  [PubMed]  [PMC] 
  46. Sudirman S, Lai CS, Yan YL, Yeh HI, Kong ZL. Histological evidence of chitosan-encapsulated curcumin suppresses heart and kidney damages on streptozotocin-induced type-1 diabetes in mice model. Sci Rep. 2019;9(1):15233. [Crossref]  [PubMed]  [PMC] 
  47. Becit M, Aydın S, Başaran N. [Evaluation of therapeutic and toxic effects of curcumin: review]. Turkiye Klin J Pharm Sci. 2017;6(2):126-42. [Crossref] 
  48. Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin. J Med Chem. 2017;60(5):1620-37. [Crossref]  [PubMed]  [PMC] 
  49. Gupte PA, Giramkar SA, Harke SM, Kulkarni SK, Deshmukh AP, Hingorani LL, et al. Evaluation of the efficacy and safety of Capsule Longvida® Optimized Curcumin (solid lipid curcumin particles) in knee osteoarthritis: a pilot clinical study. J Inflamm Res. 2019 ;12:145-52. [Crossref]  [PubMed]  [PMC] 
  50. Ghosh S, Banerjee S, Sil PC. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update. Food Chem Toxicol. 2015;83:111-24. [Crossref]  [PubMed] 
  51. Khajehdehi P. Turmeric: Reemerging of a neglected Asian traditional remedy. J Nephropathol. 2012;1(1):17-22. [Crossref]  [PubMed]  [PMC] 

Login



Contact


Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 119 - 123
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com